Physician profile
Dharmesh R Patel
NPI 1861488041
$3,229.99
in general payments reported to CMS, 2019-2025
24 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $38.78 · 2021: $753 · 2022: $841 · 2023: $548 · 2024: $509 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,980.68 | 2021-2025 | |
| Livanova USA, INC. | $261.30 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $162.37 | 2019-2025 | |
| Genentech USA, INC. | $86.62 | 2019-2022 | |
| Ge Healthcare | $78.79 | 2019-2024 | |
| Pfizer INC. | $71.98 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $71.82 | 2023-2024 | Xywav |
| Avadel Cns Pharmaceuticals, LLC | $55.65 | 2024 | Lumryz |
| Avion Pharmaceuticals | $54.28 | 2022 | |
| Abbott Laboratories | $43.92 | 2024 | Infinity |
| Biogen, INC. | $39.02 | 2024-2025 | Skyclarys |
| Sunovion Pharmaceuticals INC. | $38.20 | 2020-2021 | |
| Celgene Corporation | $32.43 | 2024 | Zeposia |
| Genzyme Corporation | $28.78 | 2025 | |
| Avanir Pharmaceuticals, INC. | $27.21 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.66 | 2021 | |
| Fisher & Paykel Healthcare INC | $25.90 | 2025 | Fisher & Paykel Healthcare |
| Argenx US, INC. | $23.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.33 | 2022 | |
| Inspire Medical Systems, INC. | $22.60 | 2025 | Inspire |
| Integra Lifesciences Corporation | $19.97 | 2022 | |
| Octapharma USA, INC. | $19.33 | 2024 | Panzyga |
| Allergan, INC. | $18.72 | 2021 | |
| Neurelis, INC. | $16.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharmesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.